Next Article in Journal
A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain
Previous Article in Journal
Canadian Initiatives for Locally Advanced Breast Cancer Research and Treatment: Inaugural Meeting of the Canadian Consortium for LABC
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 18
Issue 3
10.3747/co.v18i3.762
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Eyelash Trichomegaly Secondary to Panitumumab Therapy

by
Luc G.T. Morris
1,*,
H.S. Hochster
2 and
M.D. DeLacure
2
1
Head and Neck Service, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, NY 10022, USA
2
New York University Cancer Institute, New York University School of Medicine, New York, NY, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2011, 18(3), 145-146; https://doi.org/10.3747/co.v18i3.762
Submission received: 8 May 2011 / Revised: 18 May 2011 / Accepted: 26 May 2011 / Published: 1 June 2011

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

We report a recently encountered toxicity of therapy targeting the epidermal growth factor receptor (EGFR) that may be of interest to the wider community of oncologists. [...]
Keywords: Panitumumab; epidermal growth factor receptor; trichomegaly; eyelash; hair; targeted therapy Panitumumab; epidermal growth factor receptor; trichomegaly; eyelash; hair; targeted therapy

Share and Cite

MDPI and ACS Style

Morris, L.G.T.; Hochster, H.S.; DeLacure, M.D. Eyelash Trichomegaly Secondary to Panitumumab Therapy. Curr. Oncol. 2011, 18, 145-146. https://doi.org/10.3747/co.v18i3.762

AMA Style

Morris LGT, Hochster HS, DeLacure MD. Eyelash Trichomegaly Secondary to Panitumumab Therapy. Current Oncology. 2011; 18(3):145-146. https://doi.org/10.3747/co.v18i3.762

Chicago/Turabian Style

Morris, Luc G.T., H.S. Hochster, and M.D. DeLacure. 2011. "Eyelash Trichomegaly Secondary to Panitumumab Therapy" Current Oncology 18, no. 3: 145-146. https://doi.org/10.3747/co.v18i3.762

APA Style

Morris, L. G. T., Hochster, H. S., & DeLacure, M. D. (2011). Eyelash Trichomegaly Secondary to Panitumumab Therapy. Current Oncology, 18(3), 145-146. https://doi.org/10.3747/co.v18i3.762

Article Metrics

Back to TopTop